SGLT2i improves kidney senescence by down‐regulating the expression of LTBP2 in SAMP8 mice
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Lu Zeng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Kidney Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Senescent kidney can lead to the maladaptive repairment and predispose age‐related kidney diseases. Here, we explore the renal anti‐senescence effect of a known kind of drug, sodium‐dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence‐accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence‐related biomarkers) and structural changes (improving kidney atrophy, alleviating fibrosis, decreasing glomerular mesangial proliferation) indicate the potential value of delaying kidney senescence of SGLT2i. Senescent human proximal tubular epithelial (HK‐2) cells induced by H 2 O 2 also exhibit lower senescent markers after dapagliflozin treatment. Further mechanism exploration suggests LTBP2 have the great possibility to be the target for SGLT2i to exert its renal anti‐senescence role. Dapagliflozin down‐regulate the LTBP2 expression in kidney tissues and HK‐2 cells with senescent phenotypes. Immunofluorescence staining show SGLT2 and LTBP2 exist colocalization, and protein‐docking analysis implies there is salt‐bridge formation between them; these all indicate the possibility of weak‐interaction between the two proteins. Apart from reducing LTBP2 expression in intracellular area induced by H 2 O 2 , dapagliflozin also decrease the concentration of LTBP2 in cell culture medium. Together, these results reveal dapagliflozin can delay natural kidney senescence in non‐diabetes environment; the mechanism may be through regulating the role of LTBP2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
ORCID-Profile: Lu Zeng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zeng, L., Li, J., Gao, F., Song, Y., Wei, L., Qu, N., Chen, S., Zhao, X., Lei, Z., Cao, W., Chen, L., & Jiang, H. (2024). SGLT2i improves kidney senescence by down‐regulating the expression of LTBP2 in SAMP8 mice. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18176
Vancouver
Zeng L, Li J, Gao F, Song Y, Wei L, Qu N, et al. SGLT2i improves kidney senescence by down‐regulating the expression of LTBP2 in SAMP8 mice. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18176
BibTeX
@article{Zeng2024,
author = {Zeng, Lu and Li, Jie and Gao, Fanfan and Song, Yangyang and Wei, Limin and Qu, Ning and Chen, Shengnan and Zhao, Xue and Lei, Zitong and Cao, Wenya and Chen, Lei and Jiang, Hongli},
title = {SGLT2i improves kidney senescence by down‐regulating the expression of LTBP2 in SAMP8 mice},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18176}
}
EUVIMED